diclofenac has been researched along with Carcinoma, Basal Cell in 10 studies
Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.
diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.
Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hyaluronan (HA) in combination with diclofenac is currently undergoing clinical trials as a topical preparation in the management of osteoarthritic pain, basal-cell carcinoma and actinic keratosis." | 4.79 | Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. ( Moore, AR; Willoughby, DA, 1995) |
| "sBCC treated with diclofenac showed a significant decrease in Ki-67 (P < ." | 2.82 | The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial. ( Brinkhuizen, T; Frencken, KJ; Hoff, ML; Kelleners-Smeets, NW; Mosterd, K; Nelemans, PJ; Rennspiess, D; van der Horst, MP; van Steensel, MA; Winnepenninckx, VJ; Zur Hausen, A, 2016) |
| "Chemoprevention of nonmelanoma skin cancer should be considered in patients likely to develop numerous, invasive, or metastatic nonmelanoma skin cancers." | 2.61 | Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer. ( Council, ML; Nemer, KM, 2019) |
| "Basal cell carcinoma is a semi-malignant epithelial skin tumour with a locally destructive growth pattern but a very low tendency to metastases." | 2.43 | [Non-surgical therapy of basal cell carcinoma of the head-neck region]. ( Dissemond, J; Grabbe, S, 2006) |
| "The ability to manage non-melanoma skin cancers and pre-malignant lesions with topical pharmacologic agents is highly compelling." | 2.42 | Topical treatment strategies for non-melanoma skin cancer and precursor lesions. ( Fein, H; McGillis, ST, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, A | 1 |
| Savas, J | 1 |
| Doerfler, L | 1 |
| El-Khalawany, M | 1 |
| Saudi, WM | 1 |
| Ahmed, E | 1 |
| Mosbeh, A | 1 |
| Sameh, A | 1 |
| Rageh, MA | 1 |
| Nemer, KM | 1 |
| Council, ML | 1 |
| Brinkhuizen, T | 1 |
| Frencken, KJ | 1 |
| Nelemans, PJ | 1 |
| Hoff, ML | 1 |
| Kelleners-Smeets, NW | 1 |
| Zur Hausen, A | 1 |
| van der Horst, MP | 1 |
| Rennspiess, D | 1 |
| Winnepenninckx, VJ | 1 |
| van Steensel, MA | 1 |
| Mosterd, K | 1 |
| Micali, G | 1 |
| Lacarrubba, F | 1 |
| Dinotta, F | 1 |
| Massimino, D | 1 |
| Nasca, MR | 1 |
| Liebman, TN | 1 |
| Stein, JA | 1 |
| Polsky, D | 1 |
| Peterson, SR | 1 |
| Goldberg, LH | 1 |
| McGillis, ST | 1 |
| Fein, H | 1 |
| Dissemond, J | 1 |
| Grabbe, S | 1 |
| Moore, AR | 1 |
| Willoughby, DA | 1 |
6 reviews available for diclofenac and Carcinoma, Basal Cell
| Article | Year |
|---|---|
Nonsurgical Treatments for Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Anilides; Antineoplastic Agents; Antineoplastic Agents, Immunological; Bi | 2019 |
Topical and Systemic Modalities for Chemoprevention of Nonmelanoma Skin Cancer.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Carcinoma, Basal Cell; Carci | 2019 |
Treating skin cancer with topical cream.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Carcinoma, Basal Cell; Diclofenac; | 2010 |
Topical treatment strategies for non-melanoma skin cancer and precursor lesions.
Topics: Administration, Topical; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Ag | 2004 |
[Non-surgical therapy of basal cell carcinoma of the head-neck region].
Topics: Adjuvants, Immunologic; Adult; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Antineoplas | 2006 |
Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action.
Topics: Animals; Carcinoma, Basal Cell; Carotid Stenosis; Diclofenac; Drug Delivery Systems; Humans; Hyaluro | 1995 |
1 trial available for diclofenac and Carcinoma, Basal Cell
| Article | Year |
|---|---|
The effect of topical diclofenac 3% and calcitriol 3 μg/g on superficial basal cell carcinoma (sBCC) and nodular basal cell carcinoma (nBCC): A phase II, randomized controlled trial.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Calcitriol; Carci | 2016 |
3 other studies available for diclofenac and Carcinoma, Basal Cell
| Article | Year |
|---|---|
The combined effect of CO
Topics: Antineoplastic Agents; Carbon Dioxide; Carcinoma, Basal Cell; Diclofenac; Female; Humans; Imiquimod; | 2022 |
Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: is there a role for these agents?
Topics: Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Cy | 2013 |
New and emerging treatments for nonmelanomas and actinic keratoses.
Topics: Adjuvants, Immunologic; Aminoquinolines; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Basal C | 2003 |